Share on StockTwits

Shares of Durata Therapeutics (NASDAQ:DRTX) have earned a consensus recommendation of “Buy” from the ten brokerages that are covering the company, American Banking & Market News reports. Two equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $20.00.

A number of research firms have recently commented on DRTX. Analysts at Jefferies Group cut their price target on shares of Durata Therapeutics from $15.00 to $12.00 in a research note on Friday, August 8th. Separately, analysts at Roth Capital raised their price target on shares of Durata Therapeutics from $24.00 to $28.00 in a research note on Tuesday, July 1st. Finally, analysts at Gabelli initiated coverage on shares of Durata Therapeutics in a research note on Friday, June 20th. They set a “hold” rating on the stock.

Durata Therapeutics (NASDAQ:DRTX) traded down 1.68% on Tuesday, hitting $15.4955. The stock had a trading volume of 134,794 shares. Durata Therapeutics has a one year low of $8.10 and a one year high of $18.17. The stock’s 50-day moving average is $14.92 and its 200-day moving average is $14.81. The company’s market cap is $414.9 million.

Durata Therapeutics (NASDAQ:DRTX) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.12. Analysts expect that Durata Therapeutics will post $-2.88 EPS for the current fiscal year.

Durata Therapeutics, Inc is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses.

Receive News & Ratings for Durata Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Durata Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.